SCHEMBL716342

SCHEMBL716342

CN(C(=O)O)c1cc2cccc(Cl)c2nc1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
DHODH Q02127 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
MAPT P10636 2/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
RXRA P19793 1/20 0.33
RXRB P28702 1/20 0.33
RXRG P48443 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713672 0.87 KDR (0.46) KDRPOLBALDH1A1NPSR1CYP1A2
SCHEMBL8613 0.82 TP53 (0.43) KDRALDH1A1NPSR1CYP1A2CYP3A4
SCHEMBL26617907 0.73 KEAP1 (0.47) ALDH1A1MAPTMEN1KMT2AKDM4E
SCHEMBL17530777 0.73 PRKCH (0.35) POLBALDH1A1MAPTGAARAB9A
SCHEMBL4191610 0.72 MAOB (0.40) KDRPOLBALDH1A1CYP1A2CYP2C9
SCHEMBL2093314 0.71 TSHR (0.47) POLBALDH1A1MAPTMEN1GAA
SCHEMBL3716002 0.70 TP53 (0.37) ALDH1A1CYP3A4TRPM8MAPTMEN1
SCHEMBL1820107 0.70 POLB (0.50) POLBALDH1A1MAPTGAAFSCN1
SCHEMBL3711667 0.70 YTHDC1 (0.36) CYP3A4TRPM8GAARXRARXRB
SCHEMBL2089203 0.69 MEN1 (0.46) POLBALDH1A1NPSR1CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 KDR 437/4885POLB 1878/4885ALDH1A1 3504/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.